Divestiture Activation Pack
Global Health Industries Big Bet
2023
Work in Progress
With our global deals capabilities we are able to support our clients with any transaction - Pharma Lifescience (PLS) and Healthcare Services (HCS) M&A.
Our extensive portfolio of industry-focused deals services starting from the first strategic considerations and scoping of a target to the intense planning phase between Signing and Closing, to the first 100 days of supporting the integration. Especially when planning transactions in the highly regulated and thus complex environment our digital tools help us along the deal cycle and make processes more efficient by e.g., automating planning and aligning regulatory and production timelines.
With our PE Roll-up expertise we accommodate the requirements of routined deal maker clients to create scalable platforms that drive value creation when following their buy-&-build strategy.
Savvy health industry dealmakers who can navigate a tricky regulatory and macroeconomic landscape will continue to use M&A to innovate, grow in line with enterprise priorities and implement strategic portfolio measures. This way, they will stay ahead of their competitors.
Christian K. Moldt
Global Health Industries Deals Leader, Partner, PwC Germany
Your Health Industries Divestiture Experts
James Osborne
Big Bet Expert Divestitures US
james.j.osborne@pwc.com
+1 347-852-0031
Christian Moldt
Global Health Industries Deals Leader
christian.moldt@pwc.com
+49 1511 7604741
Andre Sassmannshausen
Big Bet Expert Divestitures EMEA
andre.sassmannshausen@pwc.com
+49 1512 6361705
Mike McNulty
Big Bet Expert Divestitures US
michael.mcnulty@pwc.com
+1 631-514-5361
Rick van Dommelen
Big Bet Expert Divestitures APAC
rick.van.dommelen@pwc.com
+31 6 51607076
Conversation starters which address divestments perspectives within Health Industries
Divestitures in M&A projects in Health Industries
Market trends
Rising interest rates and declining stock prices may put more pressure on corporate divestiture plans to help generate cash to fund new investments in an effort to optimize portfolios.
To harvest deal volumes above the terminal value in your business, a smooth separation not endangering business continuity remains key.
Currently capital markets are very restrictive due to increasing rates. However, divestments offer a source of cash for crucial investments.
Health industries
For medical need products, especially, divestments or spin-offs are the only feasible way to avoid reputational risks and ensure supply of essential medicines to patients in need.
Divestments are often the best way forward to focus on innovative and high-margin products, while established medicines can easier strive in the hands of smaller or more specialized players.
Amid an uncertain macroeconomic and regulatory environment, we expect companies within Health Industries to continue to strategically evaluate and identify non-core assets for divestment.
PwC comments
We are observing aging portfolios, nearing patent cliffs and to few streamlined product ranges across Health Industries.
PwC has unveiled the complexity drivers that are often neglected - if not addressed early and sufficiently, you will burn value and risk the deal.
Learn more about the other Big Bets
© 2023 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.